Aurobindo Pharma shares rose over 2% following its announcement of a collaboration and license agreement with a global pharma major. The partnership focuses on developing and commercializing products in the respiratory therapeutic segment.
The agreement includes an upfront payment of $25 million and shared development costs capped at $90 million for Aurobindo. The development phase is expected to take 3-5 years, with both companies sharing co-exclusive commercialization rights. Manufacturing will take place at the partner’s facility, with Aurobindo retaining the option for technology transfer in the future.
As of 9:28 am, Aurobindo Pharma shares were trading 1.84% higher at Rs 1,246.20 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
